Catégorie : Cannabis et Réduction des Risques

Cannabinoids Identification in Lung Tissues of Young Cannabis Smokers Operated for Primary Spontaneous Pneumothorax and Correlation with Pathologic Findings, Mario Bisconti et al., 2019

Cannabinoids Identification in Lung Tissues of Young Cannabis Smokers Operated for Primary Spontaneous Pneumothorax and Correlation with Pathologic Findings Mario Bisconti, Giuseppe Marulli, Roberta Pacifici, Francesco Sollitto, Giulia Nex, Xenia Trabucco, Nicoletta Pia Ardò, Maria Concetta Rotolo, Giulia De Iaco, Teodora Panza, Debora Brascia, Marcella Schiavone, Francesca Signore, Francesco Pistelli, Angela De Palma Respiration, 2019. Doi : 10.1159/000503456   Abstract Background : Several studies suggested the association between tobacco and cannabis smoking and the risk of primary spontaneous pneumothorax (PSP), but none demonstrated cannabinoids in human lung tissues. Objectives : The aim of this study was to identify cannabinoids in lung specimens of young cannabis smokers, operated [...]

Lire la suite

The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes : cannabis may have a greater impact in non-tobacco smokers, Theresa Winhusen et al., 2019

The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes : cannabis may have a greater impact in non-tobacco smokers Theresa Winhusen, Jeff Theobald, David C. Kaelber, and Daniel Lewis The American Journal of Drug and Alcohol Abuse, 2019 https://doi.org/10.1080/00952990.2019.1676433   ABSTRACT Background : Understanding the potential impact of cannabis use on cardiovascular health is increasingly important as cannabis use rises in the U.S. Objectives : This study evaluated the associations between regular cannabis use, with and without tobacco co-use, and cardiovascular outcomes. Methods : Analysis of a limited dataset obtained through IBM Watson Health Explorys, a platform integrating electronic health record data. [...]

Lire la suite

Se cacher, assumer, éviter d’en parler… comment font les parents qui fument du cannabis ?, Romain Geoffroy, 27 janvier 2019, Le Monde

Se cacher, assumer, éviter d’en parler… comment font les parents qui fument du cannabis ? On peut mener une vie familiale tranquille et pourtant, chaque jour, s’allumer un joint. Des gestes parfois difficiles à assumer avec les enfants. Par Romain Geoffroy Publié le 27 janvier 2019 à 06h34 - Mis à jour le 01 août 2019 à 17h06 QUENTIN HUGON / LE MONDE Il est 22 heures, Sébastien* s’enferme dans la salle de bains de son appartement parisien. C’est par cette fenêtre que, presque tous les soirs de la semaine, il souffle l’épaisse fumée de son joint. Une fois [...]

Lire la suite

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study, Alex Capano et al., 2019

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study Alex Capano, Richard Weaver & Elisa Burkman Postgraduate Medicine, 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Doi : 10.1080/00325481.2019.1685298   ABSTRACT Context : Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy with better safety profile. Objectives : We aim to investigate the impact [...]

Lire la suite

Medical cannabis trial will target 20,000 UK patients, Jamie Doward and Lily Gordon Brown, The Guardian, 3 novembre 2019.

Medical cannabis trial will target 20,000 UK patients Jamie Doward and Lily Gordon Brown The GUARDIAN, Published on Sun 3 Nov 2019 https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs   Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe • Medical cannabis: Why are doctors still not prescribing it? Tilray medicinal cannabis growing facility in Canada. Photograph: Tilray Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe. The move, to be unveiled on Thursday, is [...]

Lire la suite

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances, Edward James et al., 2019

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L Robertshaw & Andrew D Westwell Future Medical Chemistry, 2019 Doi : 10.4155/fmc-2018-0447 C  -  ISSN 1756-8919   “Public and mainstream scientific perceptions of these substances are shifting, and it is not difficult to envision a future in which MDMA and psilocybin play a role in contemporary medicine.” Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy   The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a [...]

Lire la suite

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users : A Pragmatic Open-Label Clinical Trial, Nadia Solowij et al., 2018

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users : A Pragmatic Open-Label Clinical Trial Nadia Solowij, Samantha J. Broyd, Camilla Beale, Julie-Anne Prick, Lisa-marie Greenwood, Hendrika van Hell, Chao Suo, Peter Galettis, Nagesh Pai, Shanlin Fu, Rodney J. Croft, Jennifer H. Martin, and Murat Yücel Cannabis and Cannabinoid Research, 2018, 3, 1,21-35 Doi : 10.1089/can.2017.0043   Abstract Introduction : Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While D9-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to [...]

Lire la suite

A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems, Daniela da Fonseca Pacheco et al.,

A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems Daniela da Fonseca Pacheco, Ana Cristina Nogueira Freitas, Adriano Monteiro C. Pimenta, Igor Dimitri Gama Duarte and Maria Elena de Lima Journal of Venomous Animals and Toxins including Tropical Diseases, 2016, 22, 34, Doi : 10.1186/s40409-016-0091-6   Abstract Background : Some peptides purified from the venom of the spider Phoneutria nigriventer have been identified as potential sources of drugs for pain treatment. In this study, we characterized the antinociceptive effect of the peptide PnPP-19 on the central nervous system and investigated the possible involvement of opioid and cannabinoid systems in its action [...]

Lire la suite

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder, Beth Wiese and Adrianne R. Wilson-Poe, 2018

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder Beth Wiese and Adrianne R. Wilson-Poe Cannabis and Cannabinoid Research, 2018, Volume 3.1,179-189. Doi : 10.1089/can.2018.0022   Abstract Introduction : The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive. Discussion : Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful for [...]

Lire la suite

No Link Between Marijuana Use and Cancer, Except TGCT, Nick Mulcahy, 2019

No Link Between Marijuana Use and Cancer, Except TGCT Nick Mulcahy Medscape Psychiatry, November 27, 2019 https://www.medscape.com/viewarticle/921889?nlid=132907_2052&src=WNL_mdplsnews_191206_mscpedit_psyc&uac=292598PZ&spon=12&impID=2194053&faf=1 More than 10 years of marijuana use is associated with the development of testicular germ cell tumor (TGCT), but the quality of the evidence is "low strength" and there is insufficient evidence to support an association between ever having used marijuana and other types of cancer. These are the conclusions from a new systematic review and meta-analysis published online today in JAMA Open Network. Lead author Mehrnaz Ghasemiesfe, MD, Northern California Institute of Research and Education, San Francisco, and colleagues explain that they wondered if marijuana smoke might cause [...]

Lire la suite